Market Cap 24.51M
Revenue (ttm) 37.06M
Net Income (ttm) -8.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -22.13%
Debt to Equity Ratio 7.74
Volume 102,800
Avg Vol 179,442
Day's Range N/A - N/A
Shares Out 62.84M
Stochastic %K 23%
Beta 1.39
Analysts Strong Sell
Price Target $5.56

Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well...

Industry: Medical Devices
Sector: Healthcare
Phone: 732 329 8885
Fax: 732 329 8650
Address:
305 College Road East, Princeton, United States
jacksonjohn750
jacksonjohn750 Jun. 29 at 2:14 PM
$CTSO They need to cancel the meeting and make a donation to the Trumps... if they want to succeed.
0 · Reply
focafoca99
focafoca99 Jun. 25 at 1:48 PM
$CTSO presented at the Life Sciences Forum and said it scheduled two FDA meetings in August for its ticagrelor and DOAC programs.
1 · Reply
Medical12
Medical12 Jun. 23 at 7:15 PM
$CTSO I still believe they will get FDA clearance in the near future.
2 · Reply
B2iDigital
B2iDigital Jun. 22 at 9:04 PM
CytoSorbents (NASDAQ: $CTSO ) brings its CytoSorb blood purification platform, with more than 300,000 devices sold across 70-plus countries, to the Life Sciences Virtual Investor Forum on June 24 at 11:30 AM ET. CytoSorbents Corporation (NASDAQ: CTSO) presents at the Life Sciences Virtual Investor Forum, co-hosted by Virtual Investor Conferences and Zacks Small Cap Research, at 11:30 AM ET on Wednesday, June 24, 2026, in a session moderated by Tom Kerr, CFA, Senior Analyst at Zacks Small Cap Research. The Life Sciences Virtual Investor Forum is a B2i Digital Featured Conference. For more details, please visit: https://b2idigital.com/vic-june-25th-life-sciences-virtual-investor-forum To register and view the presentation: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5397959/cytosorbents-corporation-nasdaq-ctso?utm_source=b2i&utm_medium=marketing&utm_campaign=0624LifeSciencesForumVIC Request a one-on-one meeting: https://app.axleaccess.com/public/events/636943bb-55cb-4a39-81b5-f658175de392?token=7b91921e-7b44-4da7-be93-ea5c37a5ed76 Phillip Chan, MD, PhD, CEO, presents for CytoSorbents alongside CFO Pete Mariani. Over the past 16 years Chan has led the company through EU approval and commercialization of its flagship CytoSorb product, and previously led healthcare and life science investments as a Partner at the NJTC Venture Fund. Mariani brings over 25 years as a strategic financial leader across high-growth medical technology companies, including CFO roles at Axogen and Hansen Medical. CytoSorbents is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, with more than 300,000 CytoSorb devices sold across more than 70 countries to date. The company is seeking U.S. FDA market authorization for an investigational product, DrugSorb-ATR, designed to remove blood-thinning drugs. Learn more at https://ir.cytosorbents.com/. Virtual Investor Conferences is an OTC Markets Group Inc. property. Learn more at www.virtualinvestorconferences.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. B2i Digital is the Official Marketing Partner of Virtual Investor Conferences. Content is informational only and is not investment advice. B2i Digital is not a broker-dealer or investment adviser.
2 · Reply
focafoca99
focafoca99 Jun. 18 at 1:04 PM
$CTSO holds a Life Sciences Forum presentation on June 24 and investor meetings on June 30.
0 · Reply
PapaRoki
PapaRoki Jun. 17 at 2:52 AM
$CTSO wicks get filled Mr. Dunky “blues clues”
1 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Jun. 16 at 12:30 AM
$CTSO CEO purchased 261,469 shares at $0.40 for a total of $104,898. Chan Phillip P. now owns 1,744,432 shares. https://ceo-buys.com
0 · Reply
FilingTracker
FilingTracker Jun. 15 at 10:26 PM
$CTSO Purchase by CEO: https://filingtracker.ai/filing/1175151/0001104659-26-074164
0 · Reply
hanovk68
hanovk68 Jun. 14 at 11:53 PM
$CTSO preliminary proxy statement out. According to this preliminary proxy statement, existing shareholders can expect a reverse split anywhere from 1:5 to 1:20 at the discretion of the Board of Directors. I take no joy in being so right about this.
1 · Reply
Stock_Catcher
Stock_Catcher Jun. 3 at 12:32 PM
$CTSO Scans
1 · Reply
Latest News on CTSO
Cytosorbents Proxy statement: Proxy filing

Jun 25, 2026, 8:00 AM EDT - 9 days ago

Cytosorbents Proxy statement: Proxy filing


Cytosorbents Proxy statement: Proxy filing

Jun 25, 2026, 8:00 AM EDT - 9 days ago

Cytosorbents Proxy statement: Proxy filing


Cytosorbents Transcript: Life Sciences Virtual Investor Forum

Jun 24, 2026, 11:30 AM EDT - 10 days ago

Cytosorbents Transcript: Life Sciences Virtual Investor Forum


Cytosorbents Proxy statement: Proxy filing

Jun 11, 2026, 8:00 AM EDT - 23 days ago

Cytosorbents Proxy statement: Proxy filing


CytoSorbents reports Q1 adjusted EPS (5c) vs. (6c) last year

2026-05-13T21:05:29.000Z - 7 weeks ago

CytoSorbents reports Q1 adjusted EPS (5c) vs. (6c) last year


Cytosorbents Earnings Call Transcript: Q1 2026

May 13, 2026, 4:30 PM EDT - 7 weeks ago

Cytosorbents Earnings Call Transcript: Q1 2026


Cytosorbents Earnings release: Q1 2026

May 13, 2026, 4:30 PM EDT - 7 weeks ago

Cytosorbents Earnings release: Q1 2026


Cytosorbents Quarterly report: Q1 2026

May 13, 2026, 4:30 PM EDT - 7 weeks ago

Cytosorbents Quarterly report: Q1 2026


Cytosorbents Slides: Q1 2026

May 13, 2026, 4:30 PM EDT - 7 weeks ago

Cytosorbents Slides: Q1 2026


Cytosorbents Earnings Call Transcript: Q4 2025

Mar 25, 2026, 4:30 PM EDT - 3 months ago

Cytosorbents Earnings Call Transcript: Q4 2025


Cytosorbents Annual report: Q4 2025

Mar 25, 2026, 4:30 PM EDT - 3 months ago

Cytosorbents Annual report: Q4 2025


Cytosorbents Earnings release: Q4 2025

Mar 25, 2026, 4:30 PM EDT - 3 months ago

Cytosorbents Earnings release: Q4 2025


Cytosorbents Slides: Q4 2025

Mar 25, 2026, 4:30 PM EDT - 3 months ago

Cytosorbents Slides: Q4 2025


CytoSorbents reports Q4 adjusted EPS (7c) vs. (3c) last year

2026-03-25T20:11:40.000Z - 3 months ago

CytoSorbents reports Q4 adjusted EPS (7c) vs. (3c) last year


CytoSorbents sees Q4 revenue $9.2M, consensus $9.85M

2026-01-12T12:10:48.000Z - 6 months ago

CytoSorbents sees Q4 revenue $9.2M, consensus $9.85M


CytoSorbents sees FY25 revenue $37M, consensus $37.67M

2026-01-12T12:10:19.000Z - 6 months ago

CytoSorbents sees FY25 revenue $37M, consensus $37.67M


Cytosorbents Transcript: Fireside Chat

Dec 15, 2025, 11:00 AM EST - 7 months ago

Cytosorbents Transcript: Fireside Chat


Cytosorbents Earnings Call Transcript: Q3 2025

Nov 13, 2025, 4:30 PM EST - 8 months ago

Cytosorbents Earnings Call Transcript: Q3 2025


Cytosorbents Earnings release: Q3 2025

Nov 13, 2025, 4:30 PM EST - 8 months ago

Cytosorbents Earnings release: Q3 2025


Cytosorbents Quarterly report: Q3 2025

Nov 13, 2025, 4:30 PM EST - 8 months ago

Cytosorbents Quarterly report: Q3 2025


Cytosorbents Slides: Q3 2025

Nov 13, 2025, 4:30 PM EST - 8 months ago

Cytosorbents Slides: Q3 2025


CytoSorbents reports Q3 adjusted EPS (4c), consensus (5c)

2025-11-13T21:21:57.000Z - 8 months ago

CytoSorbents reports Q3 adjusted EPS (4c), consensus (5c)


CytoSorbents implemented workforce and cost reduction program

2025-11-13T21:21:01.000Z - 8 months ago

CytoSorbents implemented workforce and cost reduction program


CytoSorbents provides DrugSorb-ATR regulatory update

2025-09-16T11:10:14.000Z - 10 months ago

CytoSorbents provides DrugSorb-ATR regulatory update


CytoSorbents Provides DrugSorb-ATR Regulatory Update

Sep 16, 2025, 7:00 AM EDT - 10 months ago

CytoSorbents Provides DrugSorb-ATR Regulatory Update


CytoSorbents Updates U.S. FDA Regulatory Status of DrugSorb-ATR

Aug 20, 2025, 7:00 AM EDT - 11 months ago

CytoSorbents Updates U.S. FDA Regulatory Status of DrugSorb-ATR


Cytosorbents Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

Cytosorbents Earnings Call Transcript: Q2 2025


Cytosorbents Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

Cytosorbents Quarterly report: Q2 2025


Cytosorbents Earnings release: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

Cytosorbents Earnings release: Q2 2025


CytoSorbents reports Q 2 adjusted EPS (5c) vs. (5c) last year

2025-08-07T20:05:43.000Z - 11 months ago

CytoSorbents reports Q 2 adjusted EPS (5c) vs. (5c) last year


CytoSorbents Leads a New Era in Sepsis Treatment

Jul 31, 2025, 7:00 AM EDT - 1 year ago

CytoSorbents Leads a New Era in Sepsis Treatment


Cytosorbents Slides: Investor Presentation

Jun 6, 2025, 7:00 AM EDT - 1 year ago

Cytosorbents Slides: Investor Presentation


Cytosorbents Earnings Call Transcript: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

Cytosorbents Earnings Call Transcript: Q1 2025


Cytosorbents Quarterly report: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

Cytosorbents Quarterly report: Q1 2025


Cytosorbents Earnings release: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

Cytosorbents Earnings release: Q1 2025


Cytosorbents Slides: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

Cytosorbents Slides: Q1 2025


CytoSorbents reports Q1 EPS (2c) vs. (11c) last year

2025-05-14T20:05:50.000Z - 1 year ago

CytoSorbents reports Q1 EPS (2c) vs. (11c) last year


CytoSorbents Provides Regulatory Update for DrugSorb-ATR

May 1, 2025, 4:15 PM EDT - 1 year ago

CytoSorbents Provides Regulatory Update for DrugSorb-ATR


Cytosorbents Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Cytosorbents Proxy statement: Proxy Filing


Cytosorbents Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Cytosorbents Proxy statement: Proxy Filing


Cytosorbents Earnings Call Transcript: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Cytosorbents Earnings Call Transcript: Q4 2024


Cytosorbents Earnings release: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Cytosorbents Earnings release: Q4 2024


Cytosorbents Annual report: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Cytosorbents Annual report: Q4 2024


Cytosorbents Slides: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Cytosorbents Slides: Q4 2024


CytoSorbents reiterates Q4 product revenue view $9M-$9.2M

2025-03-04T12:12:01.000Z - 1 year ago

CytoSorbents reiterates Q4 product revenue view $9M-$9.2M


CytoSorbents closes oversubscribed rights offering

2025-01-13T12:33:05.000Z - 1 year ago

CytoSorbents closes oversubscribed rights offering


CytoSorbents opens regional sales subsidiary in Dubai

2025-01-06T12:16:35.000Z - 1 year ago

CytoSorbents opens regional sales subsidiary in Dubai


Cytosorbents Slides: Investor Presentation

Dec 12, 2024, 7:00 AM EST - 1 year ago

Cytosorbents Slides: Investor Presentation


Cytosorbents Earnings Call Transcript: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Cytosorbents Earnings Call Transcript: Q3 2024


Cytosorbents Quarterly report: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Cytosorbents Quarterly report: Q3 2024


Cytosorbents Earnings release: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Cytosorbents Earnings release: Q3 2024


Cytosorbents Slides: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Cytosorbents Slides: Q3 2024


Cytosorbents Registration statement: Registration Filing

Sep 26, 2024, 8:00 AM EDT - 1 year ago

Cytosorbents Registration statement: Registration Filing


Cytosorbents Earnings Call Transcript: Q2 2024

Aug 13, 2024, 4:30 PM EDT - 2 years ago

Cytosorbents Earnings Call Transcript: Q2 2024


Cytosorbents Quarterly report: Q2 2024

Aug 13, 2024, 4:30 PM EDT - 2 years ago

Cytosorbents Quarterly report: Q2 2024


Cytosorbents Earnings release: Q2 2024

Aug 13, 2024, 4:30 PM EDT - 2 years ago

Cytosorbents Earnings release: Q2 2024


Cytosorbents Slides: Q2 2024

Aug 13, 2024, 4:30 PM EDT - 2 years ago

Cytosorbents Slides: Q2 2024


CytoSorbents Appoints Peter J. Mariani Chief Financial Officer

Aug 13, 2024, 4:18 PM EDT - 2 years ago

CytoSorbents Appoints Peter J. Mariani Chief Financial Officer


Cytosorbents Registration statement: Registration Filing

Jul 26, 2024, 8:00 AM EDT - 2 years ago

Cytosorbents Registration statement: Registration Filing


CytoSorbents Secures $20 Million Credit Facility

Jul 2, 2024, 7:00 AM EDT - 2 years ago

CytoSorbents Secures $20 Million Credit Facility


Cytosorbents Earnings Call Transcript: Q1 2024

May 9, 2024, 4:30 PM EDT - 2 years ago

Cytosorbents Earnings Call Transcript: Q1 2024


Cytosorbents Quarterly report: Q1 2024

May 9, 2024, 4:30 PM EDT - 2 years ago

Cytosorbents Quarterly report: Q1 2024


Cytosorbents Earnings release: Q1 2024

May 9, 2024, 4:30 PM EDT - 2 years ago

Cytosorbents Earnings release: Q1 2024


Cytosorbents Slides: Q1 2024

May 9, 2024, 4:30 PM EDT - 2 years ago

Cytosorbents Slides: Q1 2024


CytoSorbents Reports First Quarter 2024 Results

May 9, 2024, 4:17 PM EDT - 2 years ago

CytoSorbents Reports First Quarter 2024 Results


jacksonjohn750
jacksonjohn750 Jun. 29 at 2:14 PM
$CTSO They need to cancel the meeting and make a donation to the Trumps... if they want to succeed.
0 · Reply
focafoca99
focafoca99 Jun. 25 at 1:48 PM
$CTSO presented at the Life Sciences Forum and said it scheduled two FDA meetings in August for its ticagrelor and DOAC programs.
1 · Reply
Medical12
Medical12 Jun. 23 at 7:15 PM
$CTSO I still believe they will get FDA clearance in the near future.
2 · Reply
B2iDigital
B2iDigital Jun. 22 at 9:04 PM
CytoSorbents (NASDAQ: $CTSO ) brings its CytoSorb blood purification platform, with more than 300,000 devices sold across 70-plus countries, to the Life Sciences Virtual Investor Forum on June 24 at 11:30 AM ET. CytoSorbents Corporation (NASDAQ: CTSO) presents at the Life Sciences Virtual Investor Forum, co-hosted by Virtual Investor Conferences and Zacks Small Cap Research, at 11:30 AM ET on Wednesday, June 24, 2026, in a session moderated by Tom Kerr, CFA, Senior Analyst at Zacks Small Cap Research. The Life Sciences Virtual Investor Forum is a B2i Digital Featured Conference. For more details, please visit: https://b2idigital.com/vic-june-25th-life-sciences-virtual-investor-forum To register and view the presentation: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5397959/cytosorbents-corporation-nasdaq-ctso?utm_source=b2i&utm_medium=marketing&utm_campaign=0624LifeSciencesForumVIC Request a one-on-one meeting: https://app.axleaccess.com/public/events/636943bb-55cb-4a39-81b5-f658175de392?token=7b91921e-7b44-4da7-be93-ea5c37a5ed76 Phillip Chan, MD, PhD, CEO, presents for CytoSorbents alongside CFO Pete Mariani. Over the past 16 years Chan has led the company through EU approval and commercialization of its flagship CytoSorb product, and previously led healthcare and life science investments as a Partner at the NJTC Venture Fund. Mariani brings over 25 years as a strategic financial leader across high-growth medical technology companies, including CFO roles at Axogen and Hansen Medical. CytoSorbents is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, with more than 300,000 CytoSorb devices sold across more than 70 countries to date. The company is seeking U.S. FDA market authorization for an investigational product, DrugSorb-ATR, designed to remove blood-thinning drugs. Learn more at https://ir.cytosorbents.com/. Virtual Investor Conferences is an OTC Markets Group Inc. property. Learn more at www.virtualinvestorconferences.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. B2i Digital is the Official Marketing Partner of Virtual Investor Conferences. Content is informational only and is not investment advice. B2i Digital is not a broker-dealer or investment adviser.
2 · Reply
focafoca99
focafoca99 Jun. 18 at 1:04 PM
$CTSO holds a Life Sciences Forum presentation on June 24 and investor meetings on June 30.
0 · Reply
PapaRoki
PapaRoki Jun. 17 at 2:52 AM
$CTSO wicks get filled Mr. Dunky “blues clues”
1 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Jun. 16 at 12:30 AM
$CTSO CEO purchased 261,469 shares at $0.40 for a total of $104,898. Chan Phillip P. now owns 1,744,432 shares. https://ceo-buys.com
0 · Reply
FilingTracker
FilingTracker Jun. 15 at 10:26 PM
$CTSO Purchase by CEO: https://filingtracker.ai/filing/1175151/0001104659-26-074164
0 · Reply
hanovk68
hanovk68 Jun. 14 at 11:53 PM
$CTSO preliminary proxy statement out. According to this preliminary proxy statement, existing shareholders can expect a reverse split anywhere from 1:5 to 1:20 at the discretion of the Board of Directors. I take no joy in being so right about this.
1 · Reply
Stock_Catcher
Stock_Catcher Jun. 3 at 12:32 PM
$CTSO Scans
1 · Reply
jiggs10
jiggs10 May. 28 at 4:26 PM
$CTSO No question in my mind this gets bought out cheap
1 · Reply
NJ125
NJ125 May. 27 at 12:13 AM
$CTSO spinout HemoDefend team with VC investment assistance and let Chan continue to underperform and continue to destroy shareholder value
0 · Reply
ZacksSCR
ZacksSCR May. 21 at 9:18 PM
$CTSO Reports 1st Quarter Financial and Operating Results https://buff.ly/MrIR4mC
0 · Reply
hanovk68
hanovk68 May. 18 at 8:53 PM
$CTSO NEW ALL TIME LOW! SO SO SAD. WHY HASN’T THE BOARD ACTED???
0 · Reply
jacksonjohn750
jacksonjohn750 May. 18 at 8:20 PM
$CTSO sale
0 · Reply
hanovk68
hanovk68 May. 18 at 5:14 PM
$CTSO What do you think the reverse split will look like? How bad will existing shareholders get screwed?
0 · Reply
jacksonjohn750
jacksonjohn750 May. 18 at 12:27 PM
$CTSO I hear they are leasing parking spots.. they are trying to bring in any revenue they can
2 · Reply
NJ125
NJ125 May. 16 at 1:21 AM
$CTSO he should spin this effort out of loser patent IMHO
0 · Reply
NJ125
NJ125 May. 16 at 1:19 AM
$CTSO poor progress. Management has lost credibility IMHO- what is employee count down to in past 12 month? Parking lot certainly looks less crowded compared to a year ago. Stock price below NASDAQ $1 policy subjects company to pressure???
3 · Reply
EarningsInsider
EarningsInsider May. 14 at 5:04 AM
https://www.marketbeat.com/earnings/reports/2026-5-13-cytosorbents-co-stock/ $CTSO Cytosorbents Earnings Transcript
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 13 at 8:11 PM
$CTSO Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.08 down -300.00% YoY • Reported revenue of $8.86M up 1.57% YoY • Cytosorbents remains focused on strengthening commercial performance, reducing operating expenses, and progressing toward achieving operating cash flow breakeven in the second half of this year.
0 · Reply